Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-9.52 Insider Own5.79% Shs Outstand2.37M Perf Week6.11%
Market Cap4.53M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.23M Perf Month-12.79%
Income-17.55M PEG- EPS next Q- Inst Own39.00% Short Float11.82% Perf Quarter-9.05%
Sales0.00M P/S- EPS this Y- Inst Trans-78.55% Short Ratio4.22 Perf Half Y-68.64%
Book/sh4.54 P/B0.42 EPS next Y- ROA-57.28% Short Interest0.26M Perf Year-93.35%
Cash/sh0.73 P/C2.60 EPS next 5Y- ROE-105.32% 52W Range1.75 - 63.90 Perf YTD-75.39%
Dividend Est.- P/FCF- EPS past 5Y67.29% ROI-171.37% 52W High-97.01% Beta2.17
Dividend TTM- Quick Ratio0.62 Sales past 5Y-20.00% Gross Margin- 52W Low9.14% ATR (14)0.11
Dividend Ex-Date- Current Ratio0.62 EPS Y/Y TTM2.71% Oper. Margin0.00% RSI (14)49.08 Volatility3.30% 5.23%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-308.10% Payout- Rel Volume0.38 Prev Close1.90
Sales Surprise-14.63% EPS Surprise-79.41% Sales Q/Q- Earnings- Avg Volume62.51K Price1.91
SMA201.95% SMA50-8.53% SMA200-65.51% Trades Volume23,506 Change0.53%
Jul-15-24 07:52AM
Jun-17-24 09:00AM
May-21-24 09:00AM
May-17-24 03:52PM
08:21AM Loading…
Apr-09-24 08:21AM
Mar-05-24 09:15AM
Feb-13-24 11:45AM
Dec-29-23 12:45PM
Dec-06-23 09:15AM
Oct-19-23 09:00AM
Oct-04-23 07:30AM
Aug-14-23 08:30AM
Aug-02-23 08:30AM
Jul-31-23 09:00AM
08:30AM Loading…
Apr-12-23 08:30AM
Mar-20-23 08:55AM
Mar-08-23 08:30AM
Mar-02-23 08:30AM
Feb-28-23 08:30AM
Feb-21-23 08:45AM
Dec-06-22 09:40AM
Nov-17-22 08:00AM
Nov-14-22 08:00AM
Sep-20-22 08:00AM
Aug-30-22 08:30AM
Aug-03-22 09:45AM
Jul-29-22 09:19AM
Jul-26-22 07:30AM
Jul-12-22 09:30AM
10:30AM Loading…
Jun-21-22 10:30AM
Apr-05-22 09:15AM
Mar-24-22 09:26AM
Feb-23-22 09:15AM
Feb-20-22 08:37AM
Feb-08-22 09:15AM
Feb-07-22 08:38PM
Jan-05-22 09:15AM
Dec-29-21 09:15AM
Dec-16-21 10:50AM
Dec-01-21 10:05AM
Nov-23-21 09:25AM
Nov-18-21 09:15AM
Nov-16-21 09:25AM
Nov-15-21 09:45AM
Oct-26-21 10:30AM
Oct-19-21 10:30AM
Oct-05-21 10:00AM
Sep-22-21 11:00AM
Sep-13-21 10:00AM
Sep-09-21 10:15AM
Aug-24-21 10:17AM
Aug-23-21 08:47AM
Aug-10-21 02:30PM
Aug-05-21 10:30AM
Jul-27-21 09:15AM
Jul-07-21 09:00AM
Jun-07-21 10:02AM
May-17-21 09:00AM
May-12-21 09:00AM
May-10-21 09:00AM
Apr-28-21 10:13AM
Apr-22-21 09:20AM
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rivard PaulChief Legal OfficerAug 24 '23Buy1.11150,000166,500400,000Aug 24 05:58 PM
Rivard PaulChief Legal OfficerAug 17 '23Buy1.1225,00028,080250,000Aug 18 04:21 PM